Virtu Financial LLC lifted its position in shares of Danaher Co. (NYSE:DHR) by 85.7% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 20,176 shares of the conglomerate’s stock after purchasing an additional 9,309 shares during the period. Virtu Financial LLC’s holdings in Danaher were worth $1,873,000 at the end of the most recent reporting period.
Several other institutional investors and hedge funds have also recently bought and sold shares of the company. National Asset Management Inc. increased its position in shares of Danaher by 0.4% during the second quarter. National Asset Management Inc. now owns 3,767 shares of the conglomerate’s stock worth $318,000 after purchasing an additional 14 shares in the last quarter. Simmons Bank grew its holdings in shares of Danaher by 0.4% during the second quarter. Simmons Bank now owns 7,160 shares of the conglomerate’s stock worth $604,000 after buying an additional 26 shares during the last quarter. Horizon Investments LLC grew its holdings in shares of Danaher by 0.4% during the second quarter. Horizon Investments LLC now owns 7,828 shares of the conglomerate’s stock worth $648,000 after buying an additional 28 shares during the last quarter. WESPAC Advisors SoCal LLC grew its holdings in shares of Danaher by 1.2% during the second quarter. WESPAC Advisors SoCal LLC now owns 4,060 shares of the conglomerate’s stock worth $342,000 after buying an additional 50 shares during the last quarter. Finally, Ashford Capital Management Inc. grew its holdings in shares of Danaher by 1.4% during the second quarter. Ashford Capital Management Inc. now owns 4,942 shares of the conglomerate’s stock worth $417,000 after buying an additional 70 shares during the last quarter. Institutional investors and hedge funds own 77.05% of the company’s stock.
In other news, CFO Daniel L. Comas sold 62,989 shares of Danaher stock in a transaction that occurred on Thursday, February 1st. The shares were sold at an average price of $101.96, for a total transaction of $6,422,358.44. Following the completion of the sale, the chief financial officer now directly owns 227,805 shares in the company, valued at approximately $23,226,997.80. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, EVP William K. Daniel sold 131,066 shares of Danaher stock in a transaction that occurred on Friday, February 2nd. The shares were sold at an average price of $102.05, for a total transaction of $13,375,285.30. Following the sale, the executive vice president now owns 270,523 shares of the company’s stock, valued at $27,606,872.15. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 237,043 shares of company stock valued at $24,194,886. Insiders own 12.20% of the company’s stock.
Shares of Danaher Co. (NYSE DHR) opened at $97.54 on Tuesday. Danaher Co. has a 12-month low of $78.97 and a 12-month high of $104.82. The company has a debt-to-equity ratio of 0.39, a quick ratio of 1.05 and a current ratio of 1.43. The stock has a market cap of $67,946.36, a P/E ratio of 27.63, a PEG ratio of 2.05 and a beta of 1.04.
Danaher (NYSE:DHR) last posted its quarterly earnings results on Tuesday, January 30th. The conglomerate reported $1.19 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.16 by $0.03. Danaher had a net margin of 13.60% and a return on equity of 11.36%. The company had revenue of $5.09 billion during the quarter, compared to the consensus estimate of $4.97 billion. During the same period last year, the firm earned $1.05 EPS. The company’s revenue for the quarter was up 10.9% on a year-over-year basis. sell-side analysts anticipate that Danaher Co. will post 4.37 earnings per share for the current year.
The business also recently declared a quarterly dividend, which was paid on Friday, January 26th. Stockholders of record on Friday, December 29th were given a dividend of $0.14 per share. The ex-dividend date of this dividend was Thursday, December 28th. This represents a $0.56 dividend on an annualized basis and a dividend yield of 0.57%. Danaher’s payout ratio is 15.86%.
DHR has been the topic of a number of research reports. Stifel Nicolaus raised their price target on Danaher from $110.00 to $115.00 and gave the stock a “buy” rating in a report on Wednesday, January 31st. Cowen reissued a “buy” rating and set a $110.00 price target on shares of Danaher in a report on Tuesday, January 30th. UBS Group initiated coverage on Danaher in a report on Monday, January 22nd. They set a “buy” rating and a $99.97 price target on the stock. Robert W. Baird reissued a “buy” rating on shares of Danaher in a report on Friday, January 12th. Finally, Citigroup raised their price target on Danaher to $107.00 and gave the stock a “buy” rating in a report on Friday, December 15th. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating, fifteen have given a buy rating and one has issued a strong buy rating to the stock. The stock presently has an average rating of “Buy” and an average price target of $100.68.
COPYRIGHT VIOLATION NOTICE: “Danaher Co. (DHR) Shares Bought by Virtu Financial LLC” was originally published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this piece of content on another website, it was copied illegally and republished in violation of US & international copyright laws. The correct version of this piece of content can be viewed at https://www.dispatchtribunal.com/2018/02/20/danaher-co-dhr-shares-bought-by-virtu-financial-llc.html.
Danaher Company Profile
Danaher Corporation (Danaher) designs, manufactures and markets professional, medical, industrial and commercial products and services. The Company operates through four segments: Life Sciences, which offers a range of research tools that scientists use to study the basic building blocks of life, including genes, proteins, metabolites and cells, in order to understand the causes of disease, identify new therapies and test new drugs and vaccines; Diagnostics; which offers analytical instruments, reagents, consumables, software and services; Dental, which provides products that are used to diagnose, treat and prevent disease and ailments of the teeth, gums and supporting bone, and Environmental & Applied Solutions, which consists of various lines of business, including water quality and product identification.
Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Co. (NYSE:DHR).
Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.